A Machine Learning Aided Systematic Review and Meta-Analysis of the Relative Risk of Atrial Fibrillation in Patients With Diabetes Mellitus

Background: Meta-analysis is a widely used tool in which weighted information from multiple similar studies is aggregated to increase statistical power. However, the exponential growth of publications in key areas of medical science has rendered manual identification of relevant studies increasingly time-consuming. The aim of this work was to develop a machine learning technique capable of robust automatic study selection for meta-analysis. We have validated this approach with an up-to-date meta-analysis to investigate the association between diabetes mellitus (DM) and new-onset atrial fibrillation (AF).Methods: The PubMed online database was searched from 1960 to September 2017 where 4,177 publications that mentioned both DM and AF were identified. Relevant studies were selected as follows. First, publications were clustered based on common text features using an unsupervised K-means algorithm. Clusters that best matched the selected set of potentially relevant studies (a “training” set of 139 articles) were then identified by using maximum entropy classification. The 139 articles selected automatically on this basis were screened manually to identify potentially relevant studies. To determine the validity of the automated process, a parallel set of studies was also assembled by manually screening all initially searched publications. Finally, detailed manual selection was performed on the full texts of the studies in both sets using standard criteria. Quality assessment, meta-regression random-effects models, sensitivity analysis and publication bias assessment were then conducted.Results: Machine learning-assisted screening identified the same 29 studies for meta-analysis as those identified by using manual screening alone. Machine learning enabled more robust and efficient study selection, reducing the number of studies needed for manual screening from 4,177 to 556 articles. A pooled analysis using the most conservative estimates indicated that patients with DM had ~49% greater risk of developing AF compared with individuals without DM. After adjusting for three additional risk factors i.e., hypertension, obesity and heart disease, the relative risk was 23%. Using multivariate adjusted models, the risk for developing AF in patients with DM was similar for all DM subtypes. Women with DM were 24% more likely to develop AF than men with DM. The risk for new-onset AF in patients with DM has also increased over the years.Conclusions: We have developed a novel machine learning method to identify publications suitable for inclusion in meta-analysis.This approach has the capacity to provide for a more efficient and more objective study selection process for future such studies. We have used it to demonstrate that DM is a strong, independent risk factor for AF, particularly for women

Extreme Tele-Echocardiography: Methodology for Remote Guidance of In-Flight Echocardiography Aboard the International Space Station

Methods: In the year before launch of an ISS mission, potential astronaut echocardiographic operators participate in 5 sessions to train for echo acquisitions that occur roughly monthly during the mission, including one exercise echocardiogram. The focus of training is familiarity with the study protocol and remote guidance procedures. On-orbit, real-time guidance of in-flight acquisitions is provided by a sonographer in the Telescience Center of Mission Control. Physician investigators with remote access are able to relay comments on image quality to the sonographer. Live video feed is relayed from the ISS to the ground via the Tracking and Data Relay Satellite System with a 2- second transmission delay. The expert sonographer uses these images, along with twoway audio, to provide instructions and feedback. Images are stored in non-compressed DICOM format for asynchronous relay to the ground for subsequent off-line analysis. Results: Since June, 2009, a total of 27 resting echocardiograms and 5 exercise studies have been performed during flight. Average acquisition time has been 45 minutes, reflecting 26,000 km of ISS travel per study. Image quality has been adequate in all studies, and remote guidance has proven imperative for fine-tuning imaging and prioritizing views when communication outages limit the study duration. Typical resting studies have included 27 video loops and 30 still-frame images requiring 750 MB of storage. Conclusions: Despite limited crew training, remote guidance allows research-quality echocardiography to be performed by non-experts aboard the ISS. Analysis is underway and additional subjects are being recruited to define the impact of microgravity on cardiac structure and systolic and diastolic function

Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?

Aims: We investigated the relationship between clinically assessed left ventricular ejection fraction (LVEF) and survival in a large, heterogeneous clinical cohort. Methods and results: Physician-reported LVEF on 403 977 echocardiograms from 203 135 patients were linked to all-cause mortality using electronic health records (1998–2018) from US regional healthcare system. Cox proportional hazards regression was used for analyses while adjusting for many patient characteristics including age, sex, and relevant comorbidities. A dataset including 45 531 echocardiograms and 35 976 patients from New Zealand was used to provide independent validation of analyses. During follow-up of the US cohort, 46 258 (23%) patients who had undergone 108 578 (27%) echocardiograms died. Overall, adjusted hazard ratios (HR) for mortality showed a u-shaped relationship for LVEF with a nadir of risk at an LVEF of 60–65%, a HR of 1.71 [95% confidence interval (CI) 1.64–1.77] when ≥70% and a HR of 1.73 (95% CI 1.66–1.80) at LVEF of 35–40%. Similar relationships with a nadir at 60–65% were observed in the validation dataset as well as for each age group and both sexes. The results were similar after further adjustments for conditions associated with an elevated LVEF, including mitral regurgitation, increased wall thickness, and anaemia and when restricted to patients reported to have heart failure at the time of the echocardiogram. Conclusion: Deviation of LVEF from 60% to 65% is associated with poorer survival regardless of age, sex, or other relevant comorbidities such as heart failure. These results may herald the recognition of a new phenotype characterized by supra-normal LVEF

Extreme Tele-Echocardiography: Methodology for Remote Guidance of In-flight Echocardiography Aboard the International Space Station

Echocardiography is ideally suited for cardiovascular imaging in remote environments, but the expertise to perform it is often lacking. In 2001, an ATL HDI5000 was delivered to the International Space Station (ISS). The instrument is currently being used in a study to investigate the impact of long-term microgravity on cardiovascular function. The purpose of this report is to describe the methodology for remote guidance of echocardiography in space. Methods: In the year before launch of an ISS mission, potential astronaut echocardiographic operators participate in 5 sessions to train for echo acquisitions that occur roughly monthly during the mission, including one exercise echocardiogram. The focus of training is familiarity with the study protocol and remote guidance procedures. On-orbit, real-time guidance of in-flight acquisitions is provided by a sonographer in the Telescience Center of Mission Control. Physician investigators with remote access are able to relay comments on image optimization to the sonographer. Live video feed is relayed from the ISS to the ground via the Tracking and Data Relay Satellite System with a 2 second transmission delay. The expert sonographer uses these images along with two-way audio to provide instructions and feedback. Images are stored in non-compressed DICOM format for asynchronous relay to the ground for subsequent off-line analysis. Results: Since June, 2009, a total of 19 resting echocardiograms and 4 exercise studies have been performed in-flight. Average acquisition time has been 45 minutes, reflecting 26,000 km of ISS travel per study. Image quality has been adequate in all studies, but remote guidance has proven imperative for fine-tuning imaging and prioritizing views when communication outages limit the study duration. Typical resting studies have included 12 video loops and 21 still-frame images requiring 750 MB of storage. Conclusions: Despite limited crew training, remote guidance allows research-quality echocardiography to be performed by non-experts aboard the ISS. Analysis is underway and additional subjects are being recruited to define the impact of microgravity on cardiac structure and systolic and diastolic function

Personalised Medicine in New Zealand: A new approach to healthcare delivery

Personalised Medicine is expected to improve efficiency of healthcare delivery and reduce costs. Pharmacogenomics fits within this framework and seeks to identify individuals who are most likely to benefit from targeted interventions. The aim of this thesis was to focus on the application of personalised medicine in cardiovascular medicine, particularly as it applies to the use of antiplatelet medications, percutaneous coronary intervention, hereditary cardiac disease and population genomics. A number of clinical trials and observational studies were undertaken. This included studies of drug-drug and drug-herb interactions in Chapters Two and Three, and pharmacogenetic studies of aspirin and clopidogrel in Chapters Four to Seven. Chapter Eight summarises these findings and discusses their relevance to Maori and Pacific Peoples in New Zealand. Biorepositories are discussed in Chapter Nine and their applied clinical use in Chapter Ten. Metabolomics and proteomics were applied in Chapter Eleven to elucidate mechanisms in coronary intervention. Chapters Twelve and Thirteen include a longitudinal study of a 9p21.3 SNP, associated with coronary disease and a simulation of warfarin dose requirement using pharmacogenetics. Chapter Fourteen discusses the barriers to the adoption of genomics and what future policy requirements are needed to overcome these impediments. Results from this thesis are as follows: Concomitant medications, such the nonsteroidal drugs (ibuprofen and indomethacin) block the antiplatelet effect of aspirin. The antiplatelet response to aspirin does not appear to be influenced by genetics. Variants within the CYP2C19 gene (e.g. *2 allele) explain some of the response to clopidogrel Non-response to clopidogrel can be overcome with higher doses of the drug, however this may not be achieved with current maintenance doses (75- 150mg daily). Integrating metabolomics and proteomics has significant value in elucidating novel mechanisms behind disease and identifying biomarkers. DNA in a biorepository, linked to electronic medical records systems, has value in evaluating population genomics and in providing a clinical service The response to antiplatelet drugs is complex and not always influenced by genetics. Clopidogrel treatment, however, can be individualised using pharmacogenomics. Genomic medicine has the potential to bridge population health and individualised clinical practice. The use of genomic medicine may be advantageous in addressing ethnic disparities and may be cost effective when applied on a population basis. Ethical issues and government policy need to be addressed

Effect of Macrotroponin in a Cohort of Community Patients with Elevated Cardiac Troponin

Background Macrotroponin is an important cause of discrepancy between current high-sensitivity cardiac troponin (hs-cTn) assays, however, its clinical significance is unclear. This study examined the effects of macrotroponin and repeat testing by different hs-cTnI assays in a cohort of community patients with elevated hs-cTnI. Methods The first residual serum specimen from each patient in the community admitted to hospital with elevated hs-cTnI (Siemens hs-cTnI Centaur) was retested after immunoglobulin depletion and by 5 other hs-cTn assays. Low recovery of cTnI (<40%) following immunoglobulin depletion was considered as macrotroponin. A retrospective chart review was performed for these participants. Investigator-adjudicated diagnosis served as the reference standard. Results In our cohort of community patients with elevated troponin (n = 188), participants with macrotroponin (n = 99) often had a multifactorial or indeterminate myocardial injury (56% vs 25%) and were less likely to have acute coronary syndrome (9% vs 28%). On repeat testing of cTn on other platforms, better diagnostic performance (c-statistics) for ischemic and non-ischemic cardiac causes was observed on the Beckman Access hs-cTnI (0.74; 95% confidence interval [CI] 0.67–0.81) or the Abbott hs-cTnI Architect (0.75; CI 0.68–0.82) compared to the Siemens hs-cTnI Vista (0.62; CI 0.54–0.70; P < 0.05). This could be attributed to differences in assay reactivity for macrotroponin. Interestingly, better diagnostic performance was observed in patients without macrotroponin. Although a small number of deaths occurred (n = 16), participants with macrotroponin had better overall survival. Conclusions In the low-risk setting, the presence of macrotroponin was clinically associated with multifactorial or indeterminate causes of troponin elevation.No Full Tex